Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408732 · ClinicalTrials.gov registry record · Phase 1
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
A Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01408732: Completed Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, sponsored by University of Minnesota.
NCT01408732 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis that has completed, run by University of Minnesota. The registered enrollment target is 18 participants, below the 1,788-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01408732, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
Primary Outcome
The primary outcome measure will be severity of epistaxis as measured by the Epistaxis Severity Score (ESS). The ESS, a recently developed online questionarrie that calculates the grading system for epistaxis severity. The higher the score the more severe the nose bleeds are Scale consists of several questions with a range of scale from 0-5 The average score is calculated for a final assessment
Conditions Studied
Interventions
- OTHER Standard Treatment
- DRUG Sclerotherapy
Study Locations (1)
Minnesota
- University of Minnesota Otolaryngology Clinic - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT01408732 record still lists
NCT01408732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,788-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.
NCT01408732 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01408732 about?
NCT01408732 is a clinical study titled "Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia". The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
What is the current status of trial NCT01408732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-02. Estimated completion is 2014-09.
What conditions does trial NCT01408732 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis.
What interventions are being tested in trial NCT01408732?
The interventions under investigation include: Standard Treatment (OTHER), Sclerotherapy (DRUG).
Who is sponsoring clinical trial NCT01408732?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408732 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
RECRUITING · Phase 1
-
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
COMPLETED · Phase 1
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Ultra-low-dose Chest CT for HHT
ACTIVE NOT RECRUITING
-
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia